These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 24141807)

  • 21. Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity after permanent interstitial brachytherapy.
    Hinerman-Mulroy A; Merrick GS; Butler WM; Wallner KE; Allen Z; Adamovich E
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1367-82. PubMed ID: 15275722
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictive factors for urinary toxicity after iodine-125 prostate brachytherapy with or without supplemental external beam radiotherapy.
    Eriguchi T; Yorozu A; Kuroiwa N; Yagi Y; Nishiyama T; Saito S; Toya K; Hanada T; Shiraishi Y; Ohashi T; Shigematsu N
    Brachytherapy; 2016; 15(3):288-295. PubMed ID: 26924022
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients.
    Keyes M; Miller S; Moravan V; Pickles T; McKenzie M; Pai H; Liu M; Kwan W; Agranovich A; Spadinger I; Lapointe V; Halperin R; Morris WJ
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1023-32. PubMed ID: 19111402
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Urethral dose and increment of international prostate symptom score (IPSS) in transperineal permanent interstitial implant (TPI) of prostate cancer.
    Murakami N; Itami J; Okuma K; Marino H; Nakagawa K; Ban T; Nakazato M; Kanai K; Naoi K; Fuse M
    Strahlenther Onkol; 2008 Oct; 184(10):515-9. PubMed ID: 19016040
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-dose-rate prostate brachytherapy appears safe in patients with high baseline International Prostate Symptom Scores.
    Morgan TM; Rossi PJ; Cutrell PK; Zhang C; Press RH; Rahnema S; Sanda M; Pattaras J; Cimmino C; Hershatter B; Jani AB; Patel PR
    Brachytherapy; 2019; 18(6):793-799. PubMed ID: 31337543
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Variations in international prostate symptom scores, uroflowmetric parameters, and prostate volume after (125)I permanent brachytherapy for localized prostate cancer.
    Tanaka N; Fujimoto K; Hirao Y; Asakawa I; Hasegawa M; Konishi N
    Urology; 2009 Aug; 74(2):407-11. PubMed ID: 19376570
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of chronological changes in urinary function in patients who underwent low-dose-rate brachytherapy for prostate cancer-A randomized controlled trial of alpha-1 adrenoceptor antagonist alone versus combination with cyclooxygenase-2 inhibitor.
    Tanaka N; Torimoto K; Asakawa I; Miyake M; Anai S; Nakai Y; Fujii T; Hasegawa M; Fujimoto K
    Brachytherapy; 2018; 17(3):537-543. PubMed ID: 29402711
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Brachytherapy-related dysuria.
    Merrick GS; Butler WM; Wallner KE; Allen Z; Galbreath RW; Lief JH
    BJU Int; 2005 Mar; 95(4):597-602. PubMed ID: 15705087
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of lower urinary symptom flare with overactive bladder symptom score and International Prostate Symptom Score in patients treated with iodine-125 implant brachytherapy: long-term follow-up experience at a single institute.
    Miyake M; Tanaka N; Asakawa I; Hori S; Morizawa Y; Tatsumi Y; Nakai Y; Inoue T; Anai S; Torimoto K; Aoki K; Hasegawa M; Fujii T; Konishi N; Fujimoto K
    BMC Urol; 2017 Aug; 17(1):62. PubMed ID: 28806948
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation.
    Crook J; McLean M; Catton C; Yeung I; Tsihlias J; Pintilie M
    Int J Radiat Oncol Biol Phys; 2002 Feb; 52(2):453-60. PubMed ID: 11872292
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patient assessment of lower urinary tract symptoms using the international prostate symptom score following low-dose-rate prostate brachytherapy.
    Farris JC; Hughes RT; Steber CR; Craven TE; Frizzell BA
    Brachytherapy; 2021; 20(6):1107-1113. PubMed ID: 34353749
    [TBL] [Abstract][Full Text] [Related]  

  • 32. (125)Iodine prostate brachytherapy: outcome from the first 100 consecutive patients and selection strategies incorporating urodynamics.
    Henderson A; Cahill D; Laing RW; Langley SE
    BJU Int; 2002 Oct; 90(6):567-72. PubMed ID: 12230619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Toxicity and early biochemical outcomes from 125iodine prostate brachytherapy in the UK. A prospective study.
    Henderson A; Ismail AK; Cunningham M; Aldridge S; Loverock L; Langley SE; Laing RW
    Clin Oncol (R Coll Radiol); 2004 Apr; 16(2):95-104. PubMed ID: 15074730
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Does combination therapy with tamsulosin and trospium chloride improve lower urinary tract symptoms after SEEDS brachytherapy for prostate cancer compared with tamsulosin alone? : A prospective, randomized, controlled trial.
    Yan M; Xue P; Wang K; Gao G; Zhang W; Sun F
    Strahlenther Onkol; 2017 Sep; 193(9):714-721. PubMed ID: 28612083
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modified transurethral resection of the prostate (TURP) for men with moderate lower urinary tract symptoms (LUTS) before brachytherapy is safe and feasible.
    Brousil P; Hussain M; Lynch M; Laing RW; Langley SE
    BJU Int; 2015 Apr; 115(4):580-6. PubMed ID: 24802744
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prediction of urinary symptoms after 125iodine prostate brachytherapy.
    Kelly K; Swindell R; Routledge J; Burns M; Logue JP; Wylie JP
    Clin Oncol (R Coll Radiol); 2006 May; 18(4):326-32. PubMed ID: 16703751
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Permanent prostate brachytherapy is safe in men with severe baseline lower urinary tract symptoms.
    Winoker JS; Say RK; Mehrazin R; Stock RG; Stone NN
    Brachytherapy; 2019; 18(3):332-337. PubMed ID: 30890317
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preimplant factors affecting prostate D90 after transperineal interstitial prostate brachytherapy with loose (125)I seeds.
    Sugawara A; Nakashima J; Kunieda E; Nagata H; Mizuno R; Takeda A; Seki S; Shiraishi Y; Kouta R; Oya M; Shigematsu N
    Keio J Med; 2012; 61(3):89-94. PubMed ID: 23018491
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Segmental urethral dosimetry and urinary toxicity in patients with no urinary symptoms before permanent prostate brachytherapy.
    Thomas C; Keyes M; Liu M; Moravan V
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):447-55. PubMed ID: 18395357
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of experience and technical changes on acute urinary and rectal morbidity in low-dose prostate brachytherapy using loose seeds real-time implantation.
    Le Fur E; Malhaire JP; Nowak E; Rousseau B; Erauso A; Pene-Baverez D; Papin G; Delage F; Perrouin-Verbe MA; Fournier G; Pradier O; Valeri A
    Brachytherapy; 2013; 12(6):589-95. PubMed ID: 23669150
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.